Funds raised in Imagion’s recent Rights Issue will be used to fund the first-in-human trials for the Company’s MagSense technology. Listen to CEO Bob Proulx further discuss Imagion’s progress in this recent interview with Boardroom Media.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce